A
Angela M. Caliendo
Researcher at Brown University
Publications - 214
Citations - 14840
Angela M. Caliendo is an academic researcher from Brown University. The author has contributed to research in topics: Viral load & Virus. The author has an hindex of 56, co-authored 208 publications receiving 12910 citations. Previous affiliations of Angela M. Caliendo include Harvard University & Rhode Island Hospital.
Papers
More filters
Journal ArticleDOI
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
Eric S. Rosenberg,James M. Billingsley,Angela M. Caliendo,Steven L. Boswell,Paul E. Sax,Spyros A. Kalams,Bruce D. Walker +6 more
TL;DR: In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines.
Journal ArticleDOI
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
Camille N. Kotton,Deepali Kumar,Angela M. Caliendo,Shirish Huprikar,Sunwen Chou,Lara Danziger-Isakov,Atul Humar +6 more
TL;DR: Highlights include advances in molecular and immunologic diagnostics, improved understanding of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immunosuppressive agents, and more savvy approaches to treatment resistant/refractory disease.
Journal ArticleDOI
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly,Sharon C.-A. Chen,Carol A. Kauffman,William J. Steinbach,John W. Baddley,Paul E. Verweij,Cornelius J. Clancy,John R. Wingard,Shawn R. Lockhart,Andreas H. Groll,Tania C. Sorrell,Matteo Bassetti,Hamdi Akan,Barbara D. Alexander,David R. Andes,Elie Azoulay,Ralf Bialek,Robert W. Bradsher,Stéphane Bretagne,Thierry Calandra,Angela M. Caliendo,Elio Castagnola,Mario Cruciani,Manuel Cuenca-Estrella,Catherine F. Decker,Sujal R. Desai,Brian T. Fisher,Thomas S. Harrison,Claus Peter Heussel,Henrik Jeldtoft Jensen,Christopher C. Kibbler,Dimitrios P. Kontoyiannis,Bart Jan Kullberg,Katrien Lagrou,Frédéric Lamoth,Thomas Lehrnbecher,J. Loeffler,Olivier Lortholary,Johan Maertens,O. Marchetti,Kieren A. Marr,Henry Masur,Jacques F. Meis,C. Orla Morrisey,Marcio Nucci,Luis Ostrosky-Zeichner,Livio Pagano,Thomas F. Patterson,John R. Perfect,Zdenek Racil,Emmanuel Roilides,Marcus Ruhnke,Cornelia Schaefer Prokop,Shmuel Shoham,Monica A. Slavin,David A. Stevens,George Richard Thompson,Jose A. Vazquez,Claudio Viscoli,Thomas J. Walsh,Adilia Warris,L. Joseph Wheat,P. Lewis White,Theoklis E. Zaoutis,Peter G. Pappas +64 more
TL;DR: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Journal ArticleDOI
Better tests, better care: improved diagnostics for infectious diseases.
Angela M. Caliendo,David N. Gilbert,David N. Gilbert,Christine C. Ginocchio,Kimberly E. Hanson,Larissa S May,Thomas C. Quinn,Thomas C. Quinn,Fred C. Tenover,David Alland,Anne J. Blaschke,Robert A. Bonomo,Karen C. Carroll,Mary Jane Ferraro,Lisa R. Hirschhorn,W. Patrick Joseph,Tobi Karchmer,Ann T MacIntyre,L. Barth Reller,Audrey F. Jackson +19 more
TL;DR: The current diagnostic landscape, including unmet needs and emerging technologies, and the challenges to the development and clinical integration of improved tests are reviewed, and recommendations that address a host of identified barriers are presented.
Journal ArticleDOI
Strong Cytotoxic T Cell and Weak Neutralizing Antibody Responses in a Subset of Persons with Stable Nonprogressing HIV Type 1 Infection
Thomas Harrer,Ellen G. Harrer,Spyros A. Kalams,Tarek Elbeik,Silvija I. Staprans,Mark B. Feinberg,Mark B. Feinberg,Yunzhen Cao,David D. Ho,Tilahun Yilma,Angela M. Caliendo,R. Paul Johnson,Susan Buchbinder,Bruce D. Walker +13 more
TL;DR: It is demonstrated that a vigorous in vivo activated HIV-1-specific CTL response can be part of the host immune response in stable nonprogressive HIV- 1 infection, and that circulating activated CTL can be detected in the setting of an extremely low viral load.